Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 361 - 372 of 440

EASL Studio S1 E2: The AASLD Liver Meeting

Description

This EASL Studio has been shining the spotlight on news straight from the AASLD Liver Meeting. Watch the transatlantic discussion on key emerging concepts and the presentations that kept our experts on the edge of their seats.

Time Title
00:00-04:12

Welcome and introductions

Aleksander Krag, Odense University Hospital, Denmark

Raymond T. Chung, Massachusetts General Hospital, USA
04:12-28:26

Topic 1: News with clinical impact – NASH/NAFLD drug development

Meena Bansal, Icahn School of Medicine at Mount Sinai, USA
28:26-47:34

Topic 2: News with clinical impact: Viral Hepatitis B - Novel drug development

Joseph Lim, Yale University School of Medicine, USA
47:34-50:31

Hot topics at ILC 2022

Aleksander Krag, Odense University Hospital, Denmark

 

Moderators

  
Aleksander Krag Aleksander Krag, MD, PhD, MBA, is Professor and Head of Hepatology and Director of Odense Liver Research Centre at Odense University Hospital. He is also Chair of Health Sciences at the Danish Institute of Advanced Studies (DIAS) at University of Southern Denmark, Associate editor at Danish Medical Journal and Editor in Chief at Medicin.dk. He holds leader positions in a number of research collaborations including being the director of the Fibrosis Fatty Liver and Steatohepatitis (FLASH) Research Centre Odense, and is involved in several international organisational activities. Research is his passion with a focus on liver fibrosis, complications to cirrhosis, alcoholic liver disease and microbiome.
Raymond Chung Dr Raymond Chung is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar at Massachusetts General Hospital. He is also Professor of Medicine at Harvard Medical School. He has been an internationally recognized leader in HCV virology, pathogenesis, and hepatocarcinogenesis. In addition, he has been an Associate Editor of Hepatology, Gastroenterology, and the Journal of Infectious Diseases, and is currently President of the American Association for the Study of Liver Diseases (AASLD).

Faculty

  
Meena Bansal Dr Bansal is currently Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, Secretary for AASLD, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President, Population Health for Quality and Efficiency. She became the Director of Translational Research in the Division of Liver Diseases in 2013 and has been principal investigator for numerous clinical trials ranging from HCV to NASH. Her current research interests focus on the impact of HIV on hepatic inflammation and fibrosis and NASH.
Joseph Lim Dr Lim is a Professor of Medicine and Vice-Chief of the Section of Digestive Diseases at Yale University, where he serves as Director of Clinical Hepatology and Associate Chief of Yale-New Haven Health System (YNHHS) Digestive Health. In his role at Yale Liver Center, he directs an active clinical trials program evaluating novel investigational agents for viral hepatitis and NASH. He serves on the AASLD CME Committee (Chair), Scientific Program Committee, and Viral Hepatitis Elimination Taskforce.
Log in to post comments

EASL Studio Special Edition: Highlights of Liver Cancer Summit 2022

Description

The highlights of EASL's Liver Cancer Summit 2022 -  What is practice changing right now and where are the current controversies?

How do our experts interprete the new data on Immunotherapy in HCC and CCA, and what to expect in 2022: Upcoming trials, New combinations, New biomarkers

Watch on-demand the session that was broadcast Friday 4 February 2022.

 

 

Moderator

  
Tom Luedde Tom Lüdde is Professor and Chair of the Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf (Germany). He was a visiting scientist at the Lineberger Cancer Centre (USA) and was appointed Professor at the University of Aachen. His main research interests are inflammation in metabolic liver disease and cancer and artificial intelligence and deep learning in gastrointestinal diseases and cancer. He is the recipient of the Ernst Jung Career Advancement Award and the Thannhauser Award from the German Association of Digestive Disease (DGVS).

Faculty

  
Bruno Sangro Prof. Bruno Sangro is Director of the Liver Unit and Co-Director of the HPB Oncology Area at Clínica Universidad de Navarra in Pamplona, Spain. He is also Professor of Internal Medicine and leads an active research group in the Spanish Network for Biomedical Research on Hepatic and Digestive Diseases (CIBEREHD), focused on therapeutic innovation in the field of liver cancer. He currently serves as Past President of the International Liver Cancer Association.
Tim Greten Dr Greten is co-chair of the Center of Excellence in Immunology, member of the Center for Advanced Preclinical Research oversight. In 2010 he joined CCR's Medical Oncology Branch as head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015 and Deputy Branch Chief in 2018. Dr. Greten has published more than 200 peer-reviewed papers on basic tumor immunology, translational research studies in hepatocellular carcinoma (HCC) as well as on clinical trials in different gastrointestinal malignancies, including HCC.
Log in to post comments
Rare Liver Diseases
ERN Rare-Liver on-demand Webinar: Autoimmune sclerosing cholangitis & PSC: the spectrum of bile duct changes from childhood and through adult life

ERN Rare-Liver on-demand Webinar: Autoimmune sclerosing cholangitis & PSC: the spectrum of bile duct changes from childhood an...

On-demand Webinars
View
General Hepatology
Quiz: 63-year-old Irish lawyer with healthy appearance (bronzed skin) and a normal body mass index

Quiz: 63-year-old Irish lawyer with healthy appearance (bronzed skin) and a normal body mass index

Quiz
View
General Hepatology
EASL Studio Podcast S3 E5: JHEP Live: Stigma and alcohol

EASL Studio Podcast S3 E5: JHEP Live: Stigma and alcohol

EASL Studio
View
General Hepatology
EASL Studio Podcasts S3 E1: JHEP Live: Covid vaccination and associated autoimmune hepatitis

EASL Studio Podcasts S3 E1: JHEP Live: Covid vaccination and associated autoimmune hepatitis

Podcasts
View
Cirrhosis & Complications
EASL Studio Podcasts S3 E2: Liver transplantation for ACLF: Opportunities, challenges and pitfalls

EASL Studio Podcasts S3 E2: Liver transplantation for ACLF: Opportunities, challenges and pitfalls

Podcasts
View
Metabolism, Alcohol & Toxicity
EASL Studio Podcast S3 E4: Special Edition: Highlights of EASL NAFLD Summit 2022

EASL Studio Podcast S3 E4: Special Edition: Highlights of EASL NAFLD Summit 2022

Podcasts
View
COVID-19 and the liver
Quiz: A 46-year-old patient with severe COVID-19 survives due to intensive care with multiple drugs and prolonged artificial ventilation and extracorporeal membrane oxygenation

Quiz: A 46-year-old patient with severe COVID-19 survives due to intensive care with multiple drugs and prolonged artificial v...

Quiz
View
Viral Hepatitis
Quiz: A 24-year-old woman presents at week 20 of her pregnancy.

Quiz: A 24-year-old woman presents at week 20 of her pregnancy.

Quiz
View
Metabolism, Alcohol & Toxicity
Quiz: Fibrosis is the most important prognostic factor in NAFLD, correlating with liver-related outcomes and mortality.

Quiz: Fibrosis is the most important prognostic factor in NAFLD, correlating with liver-related outcomes and mortality.

Quiz
View
General Hepatology
Quiz: A 34-year-old woman presents to the emergency department with a 1 week history of fatigue, malaise, lethargy and jaundice.

Quiz: A 34-year-old woman presents to the emergency department with a 1 week history of fatigue, malaise, lethargy and jaundic...

Quiz
View
Displaying 361 - 372 of 440